We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
-1.44%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$40.3B
AUM Growth
-$3.3B
(-7.6%)
Cap. Flow
-$1.89B
Cap. Flow
% of AUM
-4.68%
Top 10 Holdings %
Top 10 Hldgs %
21.18%
Holding
1,160
New
85
Increased
251
Reduced
431
Closed
113
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVLR
Avalara, Inc.
AVLR
|
+$150M |
| 2 |
EOG Resources
EOG
|
+$128M |
| 3 |
TJX Companies
TJX
|
+$122M |
| 4 |
RTX Corp
RTX
|
+$107M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$105M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$365M |
| 2 |
Burlington
BURL
|
+$216M |
| 3 |
Textron
TXT
|
+$190M |
| 4 |
Dollar Tree
DLTR
|
+$126M |
| 5 |
ExxonMobil
XOM
|
+$124M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.31% |
| 2 | Healthcare | 17.41% |
| 3 | Financials | 15.7% |
| 4 | Consumer Discretionary | 9.78% |
| 5 | Industrials | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
851
Regal Rexnord
RRX
$11.9B
| $2.1M | 0.01% |
15,000
-179,812
| -92% | -$24.2M |
|
852
Larimar Therapeutics
LRMR
$436M
| $2.08M | 0.01% |
651,680
+475,000
| +269% | +$1.19M |
|
|
VAXX
853
DELISTED
Vaxxinity, Inc. Class A Common Stock
VAXX
| $1.98M | ﹤0.01% |
1,001,670
| – | – |
|
|
KDNY
854
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.97M | ﹤0.01% |
100,000
-50,000
| -33% | -$1M |
|
|
EPIX
855
DELISTED
ESSA Pharma
EPIX
| $1.9M | ﹤0.01% |
1,042,531
| – | – |
|
|
GNFT
856
DELISTED
Genfit
GNFT
| $1.88M | ﹤0.01% |
+516,055
| New | +$2.16M |
|
857
News Corp Class B
NWS
$18.3B
| $1.88M | ﹤0.01% |
121,734
-3,600
| -3% | -$61.4K |
|
858
Alkermes
ALKS
$8.11B
| $1.79M | ﹤0.01% |
80,000
-1,010,000
| -93% | -$26.3M |
|
|
MPT
859
Medical Properties Trust
MPT
$2.75B
| $1.78M | ﹤0.01% |
+150,000
| New | +$2.27M |
|
|
CBAY
860
DELISTED
Cymabay Therapeutics
CBAY
| $1.75M | ﹤0.01% |
500,000
| – | – |
|
861
Rezolute
RZLT
$453M
| $1.73M | ﹤0.01% |
631,690
| – | – |
|
|
KZR
862
DELISTED
Kezar Life Sciences
KZR
| $1.72M | ﹤0.01% |
20,000
-28,000
| -58% | -$2.72M |
|
863
TScan Therapeutics
TCRX
$49.9M
| $1.68M | ﹤0.01% |
550,000
| – | – |
|
864
Cabaletta Bio
CABA
$450M
| $1.65M | ﹤0.01% |
2,541,645
| – | – |
|
|
CNTB
865
Connect Biopharma Holdings
CNTB
$138M
| $1.65M | ﹤0.01% |
1,277,519
-400,000
| -24% | -$481K |
|
866
Canadian Natural Resources
CNQ
$94.8B
| $1.63M | ﹤0.01% |
+70,000
| New | +$1.81M |
|
867
Aligos Therapeutics
ALGS
$34.1M
| $1.62M | ﹤0.01% |
58,931
| – | – |
|
|
OTLY
868
Oatly Group
OTLY
$437M
| $1.59M | ﹤0.01% |
30,250
-6,750
| -18% | -$467K |
|
869
Vista Energy
VIST
$7.36B
| $1.57M | ﹤0.01% |
166,420
+100,000
| +151% | +$860K |
|
870
NuScale Power
SMR
$3.89B
| $1.51M | ﹤0.01% |
129,260
| – | – |
|
|
ETRN
871
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $1.5M | ﹤0.01% |
200,000
-3,325,000
| -94% | -$27.8M |
|
|
FARM
872
DELISTED
Farmer Brothers
FARM
| $1.41M | ﹤0.01% |
301,229
| – | – |
|
|
UBX
873
DELISTED
Unity Biotechnology
UBX
| $1.38M | ﹤0.01% |
+350,000
| New | +$2.21M |
|
874
Host Hotels & Resorts
HST
$16B
| $1.38M | ﹤0.01% |
86,833
+4,900
| +6% | +$85.4K |
|
875
Werner Enterprises
WERN
$2.21B
| $1.37M | ﹤0.01% |
36,545
+25,874
| +242% | +$1.05M |
|
Similar funds
Adage Capital Partners's Q3 2022 Portfolio in Review
As of Q3 2022, Adage Capital Partners held 1,160 positions worth $40.3B, down 7.6% from $43.6B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners withdrew a net $1.89B in Q3 2022, closing 113 positions and reducing 431 holdings. Its most notable exit was Vonage Holdings Corporation, an estimated $101M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 23% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Avalara, Inc. worth $153M.
- Adage Capital Partners's largest Q3 2022 buy was Avalara, Inc.: 1,670,000 shares worth $153M.
- Adage Capital Partners added most to EOG Resources in Q3 2022, an estimated $128M increase.
- Adage Capital Partners's biggest Q3 2022 reduction was Royalty Pharma, cutting an estimated $365M.
- Adage Capital Partners fully exited Vonage Holdings Corporation in Q3 2022, selling an estimated $101M.
- Adage Capital Partners's ten largest holdings make up 21% of its $40.3B portfolio in Q3 2022.
- Adage Capital Partners opened 85 new positions and closed 113 in Q3 2022.
- Adage Capital Partners's portfolio value fell 7.6% quarter-over-quarter to $40.3B.
Based on Adage Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.